Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
This quick guide explains typical candidates for credit builder loans and the situations where they can be most effective in building credit.
24,219 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
NVIDIA’s push beyond chips is drawing investor attention to life sciences. This article breaks down what Jensen Huang...
A dramatic insider move at Apogee comes after a steep stock rise. This article breaks down the possible meanings, ris...
Trump's remarks about controlling the Strait of Hormuz sent risk-off waves through crypto markets, with Bitcoin hover...
When a global star faces health setbacks, a comeback isn’t just about a setlist. This story looks at Lewis Capaldi’s ...
U.S. stocks faced a bifurcated session as analysts issued fresh price targets and ratings on key names, signaling the...
Nvidia stock sits at a crossroads as AI demand sustains rapid growth. A new price prediction assesses the odds of a d...
July has brought headlines that test investors' nerves. This piece breaks down what drove stock moves today, what Luc...
Cantor Fitzgerald partners with Securitize to explore blockchain-native IPO shares, signaling a shift toward real-tim...
Meta Platforms is gaining momentum in July 2026 as advertisers lean into AI-powered targeting. This piece explains wh...
If you keep cash in a basic checking or under the mattress, you may be missing out on meaningful growth. This guide s...
Mid-year, Figma faces a volatile path as investors weigh AI-led growth against high valuation. A refreshed price pred...